Latest Breaking News On - Jason rando - Page 3 : comparemela.com

KemPharm : to Present at the Benzinga Healthcare Small Cap Conference

Cantex Pharmaceuticals Announces Sale of Equity Interest in Chimerix, Inc.

Cantex Pharmaceuticals Announces Sale of Equity Interest in Chimerix, Inc.

AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients

Published: Jan 26, 2021 DELRAY BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced the activation of two additional clinical trial sites in Poland for the extension arm of the Phase 2b OPTION 2 study investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF). Additional sites were added in Europe to minimize any potential patient enrollment delays during the ongoing COVID-19 pandemic. The two sites in Poland, as well as the active clinical trial sites in the U.S., are actively enrolling patients, and the Company anticipates reporting topline data during the first quarter 2021.